Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV
Status:
Terminated
Trial end date:
2018-01-22
Target enrollment:
Participant gender:
Summary
Prevention and control of Chemotherapy-Induced Nausea and Vomiting (CINV) are most important
in treatment of cancer patients. CINV is one of the most distressing severe side effects of
cancer treatment and can have a significant impact on a patient's quality of life. The
chemotherapy agents that cause the worst degree of nausea and vomiting are categorized into
two groups: moderately emetogenic chemotherapy (MEC) and highly emetogenic chemotherapy
(HEC). Nausea and vomiting that occurs within the first day of the administration of
chemotherapy agents is considered acute CINV, while nausea and vomiting following 24 hours of
the administration of chemotherapy agents is considered delayed CINV. Refractory CINV occurs
when patients develop CINV during subsequent cycles of chemotherapy when drugs preventing
vomiting and nausea (antiemetic prophylaxis) has not been successful in controlling CINV in
earlier cycles. The purpose of this study is to assess the efficacy of Akynzeo in the
treatment of refractory CINV